Journal of Eye and Ophthalmology

Journal of Eye and Ophthalmology

ISSN 2055-2408
Case report

Efficacy of aflibercept for the treatment of chronic non-ischemic CRVO-associated macular edema after treatment with other anti-VEGF agents

Bozho Todorich1,2*, Phoebe Lin1,2, Christine Shieh1,2 and Sharon Fekrat1,2

*Correspondence: Bozho Todorich

1. Duke University Eye Center, Erwin Road, PO Box 3802, Durham, NC 27710, USA.

Author Affiliations

2. Durham Veterans Affairs Medical Center, 508 Fulton Street, Durham, NC 27705, USA.


Objective: To describe a patient with a perfused CRVO that responded to intravitreal aflibercept after prior treatment with intravitreal bevacizumab and intravitreal ranibizumab.

Design: Retrospective report of a case.

Methods: Institutional retrospective review of a single case of a patient with CRVO-related macular edema treated with anti-VEGF agents (bevacizumab, ranibizumab and aflibercept). Baseline demographics, visual acuity and OCT scans are reported.

Results: A 62 year old male with a perfused CRVO with marked cystoid macular edema was treated with intravitreal aflibercept and subsequently experienced significant improvement in visual acuity and central foveal thickness. This effect was observed despite prior treatment with intravitreal bevacizumab as well as intravitreal ranibizumab.

Conclusion: Intravitreal aflibercept is a viable treatment option for macular edema due to CRVO in eyes even after prior treatment with other anti-VEGF agents.

Keywords: CRVO, bevacizumab, ranibizumab, aflibercept, VEGF, macular edema

ISSN 2055-2408
Volume 1
Abstract Download